Hemab Therapeutics Holdings, Inc. Common Stock (NASDAQ: COAG) is a Healthcare company (Biotechnology) with a market capitalization of $2.3B. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), Hemab Therapeutics Holdings, Inc. Common Stock had a Maz Rating of 3.25 out of 5 (B+, Buy), ranked against the other companies in its sector. Its strongest factor then was Financial Health (4.98), among the strongest in its sector; its weakest was Valuation (1.46), among the most expensive in its sector. The other factors: Profitability 2.93 (around the middle of its sector). The current rating is for members: log in to see it.
At $49.02, Hemab Therapeutics Holdings, Inc. Common Stock trades at 3.2x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -36.6%, return on invested capital of -10.9% and a free cash flow yield of -1.9%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 35.85. Over the past 52 weeks the share price ranged from $23.00 to $55.42, with a beta of 1.85.
Hemab Therapeutics Holdings, Inc. Common Stock does not currently pay a dividend.
3 Wall Street analyst ratings cover the stock: 3 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.